Gepotidacin (GSK2140944) in vitro activity against gram-positive and gram-negative bacteria

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 7, 2017, Pages

  Flamm, R K ^a   Farrell, D J ^a,c   Rhomberg, P R ^a   Scangarella Oman, N E ^b   Sader, H S ^a  

^a JMI LABORATORIES   (United States)

^b GLAXOSMITHKLINE   (United States)

^c Saskatchewan Disease Control Laboratory   (Canada)

Author keywords

Gepotidacin; Minimum bactericidal activity; Postantibiotic effect

Indexed keywords

AZITHROMYCIN; AZTREONAM; CEFTRIAXONE; COTRIMOXAZOLE; GENTAMICIN; GEPOTIDACIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; TETRACYCLINE; VANCOMYCIN; ACENAPHTHENE DERIVATIVE; ANTIINFECTIVE AGENT; FUSED HETEROCYCLIC RINGS;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; DRUG POTENTIATION; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST;

ACENAPHTHENES; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ESCHERICHIA COLI; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HETEROCYCLIC COMPOUNDS, 3-RING; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 85021646687     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00468-17     Document Type: Article

References (16)

1. Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR, Gorrec F, Gior-dano I, Hann MM, Hennessy A, Hibbs M, Huang J, Jones E, Jones J, Brown KK, Lewis CJ, May EW, Saunders MR, Singh O, Spitzfaden CE, Shen C, Shillings A, Theobald AJ, Wohlkonig A, Pearson ND, Gwynn MN. 2010. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466:935–940. https://doi.org/10.1038/nature09197.
2. Biedenbach DJ, Bouchillon SK, Hackel M, Miller LA, Scangarella-Oman NE, Jakielaszek C, Sahm DF. 2016. In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens. Antimicrob Agents Chemother 60: 1918–1923. https://doi.org/10.1128/AAC.02820-15.
3. Jones RN, Fedler KA, Scangarella-Oman NE, Ross JE, Flamm RK. 2016. Multicenter investigation of gepotidacin (GSK2140944) agar dilution quality control determinations for Neisseria gonorrhoeae ATCC 49226. Antimicrob Agents Chemother 60:4404–4406. https://doi.org/10.1128/AAC.00527-16.
4. Flamm RK, Sader HS, Rhomberg PR, Scangarella-Oman NE, Farrell DJ. 2016. Gepotidacin (GSK2140944) in vitro activity against Gram-positive and Gram-negative bacteria (MBC/MIC, kill kinetics, checkerboard, PAE/ SME tests), abstr 460. ASM Microbe, Boston, MA, 16 to 20 June 2016.
5. Farrell DJ, Sader HS, Rhomberg PR, Scangarella-Oman NE, Flamm RK. 2016. Gepotidacin (GSK2140944) in vitro activity against Neisseria gonorrhoeae (MIC/MBC, kill kinetics, checkerboard, PAE/SME tests), abstr 461. ASM Microbe, Boston, MA, 16 to 20 June 2016.
6. Lahiri SD, Kutschke A, McCormack K, Alm RA. 2015. Insights into the mechanism of inhibition of novel bacterial topoisomerase inhibitors from characterization of resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother 59:5278–5287. https://doi.org/10.1128/AAC.00571-15.
7. Nayar AS, Dougherty TJ, Reck F, Thresher J, Gao N, Shapiro AB, Ehmann DE. 2015. Target-based resistance in Pseudomonas aeruginosa and Escherichia coli to NBTI 5463, a novel bacterial type II topoisomerase inhibitor. Antimicrob Agents Chemother 59:331–337. https://doi.org/10.1128/AAC.04077-14.
8. Dougherty TJ, Nayar A, Newman JV, Hopkins S, Stone GG, Johnstone M, Shapiro AB, Cronin M, Reck F, Ehmann DE. 2014. NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against Gram-negative bacteria and in vivo efficacy. Antimicrob Agents Chemother 58:2657–2664. https://doi.org/10.1128/AAC.02778-13.
9. Clinical and Laboratory Standards Institute. 2015. M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard—tenth edition. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Clinical and Laboratory Standards Institute. 1999. M26-A. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Clinical and Laboratory Standards Institute. 2016. M100-S26. Performance standards for antimicrobial susceptibility testing; 26th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Koeth LM. 2016. Tests to assess bactericidal activity. In Leber AL (ed), Clinical microbiology procedures handbook, 4th ed, vol 2. ASM Press, Washington, DC.
13. Moody J. 2004. Susceptibility tests to evaluate synergism, p 5.12.11–15.12.23. In Isenberg HD (ed), Clinical microbiology procedures handbook, vol 5. ASM Press, Washington, DC.
14. Odenholt-Tornqvist I. 1993. Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem. J Antimicrob Chemother 31:881–892. https://doi.org/10.1093/jac/31.6.881.
15. Odenholt-Tornqvist I, Lowdin E, Cars O. 1992. Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin. Antimicrob Agents Chemother 36:1852–1858. https://doi.org/10.1128/AAC.36.9.1852.
16. Spangler SK, Lin G, Jacobs MR, Appelbaum PC. 1998. Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci. Antimicrob Agents Chemother 42:1253–1255.